The European Medicines Agency (EMA) has accepted for review Samsung Bioepis Co. Ltd.'s marketing authorization application for SB5, a biosimilar candidate referencing AbbVie Inc.'s top-selling product Humira (adalimumab), and taking the South Korean firm a step closer to launching its third biosimilar in Europe and further expanding its presence in the region.
Humira had worldwide net revenues of $10.2bn in the nine months ended Sept. 30, accounting for about 63% of the...